6667 Stock Overview
A genetic testing platform company, provides consumer genetic testing and cancer screening services in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mega Genomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.75 |
| 52 Week High | HK$12.40 |
| 52 Week Low | HK$7.64 |
| Beta | 1.54 |
| 11 Month Change | -15.02% |
| 3 Month Change | -20.84% |
| 1 Year Change | -9.14% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.94% |
Recent News & Updates
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28
Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Recent updates
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Shareholder Returns
| 6667 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -1.9% | -5.1% | -3.9% |
| 1Y | -9.1% | -37.9% | -3.3% |
Return vs Industry: 6667 exceeded the Hong Kong Healthcare industry which returned -37.9% over the past year.
Return vs Market: 6667 underperformed the Hong Kong Market which returned -3.3% over the past year.
Price Volatility
| 6667 volatility | |
|---|---|
| 6667 Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 5.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.2% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6667's share price has been volatile over the past 3 months.
Volatility Over Time: 6667's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 214 | n/a | www.megagenomics.cn |
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services, including brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, such as hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; and telomere length genetic testing that assesses the cell age and aging rate of a person.
Mega Genomics Limited Fundamentals Summary
| 6667 fundamental statistics | |
|---|---|
| Market cap | HK$1.86b |
| Earnings (TTM) | HK$34.93m |
| Revenue (TTM) | HK$174.96m |
51.9x
P/E Ratio10.4x
P/S RatioIs 6667 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6667 income statement (TTM) | |
|---|---|
| Revenue | CN¥159.71m |
| Cost of Revenue | CN¥67.10m |
| Gross Profit | CN¥92.62m |
| Other Expenses | CN¥60.73m |
| Earnings | CN¥31.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 57.99% |
| Net Profit Margin | 19.97% |
| Debt/Equity Ratio | 3.3% |
How did 6667 perform over the long term?
See historical performance and comparison